Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

Sponsor
Nurix Therapeutics, Inc.
Study ID
NCT07516093
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • NX-5948 — DRUG
    Administered orally once daily
  • Pirtobrutinib — DRUG
    Administered orally once daily per prescribing information

Study Details

The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who are relapsed or refractory to prior covalent Bruton tyrosine kinase inhibitor (cBTKi) treatment.

Key Dates

First listed
Apr 7, 2026
Start date
Jun 30, 2026
Status verified
Apr 2026
Primary completion
Oct 31, 2029
Completion
Jun 30, 2032

Study Design

Enrollment
620 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A: NX-5948
  • Experimental: Arm B: Pirtobrutinib

Primary Outcome Measure

Progression-free survival (PFS) as assessed by Independent Review Committee (IRC) [ Time Frame: Up to approximately 3.5 years ]

Central Contacts

Find similar trials

Nationwide
Leukemia (other) trialsOncology trialsBlood cancer trials

Related Studies